For more information on NEBNext reagents for library preparation, visit NEBNext.com.
NEBNEXT® is a registered trademark of New England Biolabs, Inc.
Ultra™ is a trademark of New England Biolabs, Inc.
About Population Genetics Technologies Ltd
Population Genetics Technologies Ltd was founded in 2005 by Nobel Laureate Dr Sydney Brenner; the founder of Applied Biosystems and of Lynx Therapeutics, Dr Sam Eletr; and the founder of Molecular Tool and Red Abbey Ventures, Dr Philip Goelet. The company has developed proprietary technologies that transform the economic viability of performing large scale genetic population studies, and that allow the sensitive and high confidence detection of rare variants and mutations for use in research and in guiding clinical decision making.
About New England Biolabs
Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, library preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distrib
|SOURCE New England Biolabs|
Copyright©2012 PR Newswire.
All rights reserved